Ganagliflozin Proline Tablets | China Drugs List

Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.

Company: Huisheng Biopharmaceutical Co., Ltd.
Medicine type: Chemical medicine
Therapeutic area: Endocrinology & metabolism
Indications recorded in the public source: To improve glycemic control in adults with type 2 diabetes: (1) as monotherapy alongside diet and exercise; (2) in combination with metformin hydrochloride alongside diet and exercise when metformin hydrochloride alone does not provide adequate glycemic control. Important limitations of use: not indicated for type 1 diabetes or diabetic ketoacidosis.
Indication source and scope: Source date(s): 2024, 2026. Indications transcribed from the public NHSA manufacturer submission; this is not verification of the complete current label.
Prescribing-information limitations: A verifiable complete prescribing-information document has not yet been obtained. Available approval records or NHSA submissions support the indications shown; the latest full scope needs confirmation.
China availability status: Historical Chinese approval verified; current continuous market availability has not been checked for every product.
Overseas status: Market-by-market verification pending.
Insurance classification: Included in national insurance (Category B)
Insurance edition: 2025 edition; effective 1 January 2026
Insurance restrictions: Limited to type 2 diabetes.
Insurance period: 2025-01-01 to 2026-12-31
Insurance verification notes: Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.

Sources

Open the interactive record, public price references and discussions